IMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ImageneBio Inc (IMA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive catalysts, has weak financial performance, and faces significant challenges as highlighted by analysts. Additionally, there are no strong trading signals or favorable technical indicators to support a buy decision.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 37.255, showing no clear signal. Moving averages are converging, suggesting indecision in price movement. The stock is trading near its support level of 6.756, with resistance at 7.483. Overall, the technical indicators do not favor a buy.
The appointment of Dr. Ben Porter-Brown as Chief Medical Officer and plans to expand the Phase 2b trial internationally could potentially improve the company's operational outlook in the long term.
Wedbush downgraded the stock to Underperform with a price target of $2, citing high development costs, reliance on a single asset, limited catalysts, and strong competition. Additionally, the stock has a high probability of declining in the short to medium term based on historical patterns.
In Q3 2025, the company reported zero revenue, a net loss of $25.63 million (up 150.39% YoY), and an EPS of -3.01 (up 18.50% YoY). While there is some improvement in net income and EPS, the company remains unprofitable with no revenue growth.
Wedbush downgraded the stock to Underperform from Neutral, with a price target reduced from $23 to $2. Analysts recommend avoiding the stock unless significant changes occur, such as gaining a development partner or shifting focus to a new indication.
